glp 1 and spironolactone The dual impact of GLP-1 receptor agonists on metabolic reproductive health in polycystic ovary syndrome: insights from human and animal trials Current Insights, Advantages and Challenges

Patent number: US10278961B2, CN108997332B, US20230138576A1

doi: 10.1007/s001250050348 61 SchenkerSDawberNHSchmidR

About Blue Health Intelligence Blue Health Intelligence (BHI) is a trade name of Health Intelligence Company LLC, an independent licensee of the Blue Cross Blue Shield Association

Limitations, Long-Term Considerations, and When to Consider Phentermine-Topiramate Even though it works well, phentermine has important limitations: FDA approval remains limited to short-term use Appetite suppression may diminish over time (tolerance) Not ideal for patients with uncontrolled anxiety, insomnia, or hypertension Does not improve metabolic markers (A1C, cholesterol) like GLP-1 therapies For longer-term taste control, combination options such as phentermine-topiramate may offer more sustained benefit under medical supervision

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad, Iran

The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis